William D. McClellan's most recent trade in Reata Pharmaceuticals Inc - Ordinary Shares - Class A was a trade of 5,000 Class B common stock done . Disclosure was reported to the exchange on July 28, 2023.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Reata Pharmaceuticals Inc ... | William D. McClellan | Director | 28 Jul 2023 | 5,000 | 0 | - | - | Class B common stock | ||
| Reata Pharmaceuticals Inc ... | William D. McClellan | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Jul 2023 | 5,000 | 4,500 | - | - | Stock Option (right to buy) | |
| Reata Pharmaceuticals Inc ... | William D. McClellan | Director | Sale of securities on an exchange or to another person at price $ 164.49 per share. | 28 Jul 2023 | 5,000 | 6,017 (0%) | 0% | 164.5 | 822,442 | Class A common stock |
| Reata Pharmaceuticals Inc ... | William D. McClellan | Director | 28 Jul 2023 | 5,000 | 11,017 (0%) | 0% | - | Class A common stock | ||
| Reata Pharmaceuticals Inc ... | William D. McClellan | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Jul 2023 | 5,000 | 5,000 | - | - | Class B common stock | |
| Reata Pharmaceuticals Inc ... | William D. McClellan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2023 | 2,137 | 2,137 | - | - | Stock Option (right-to-buy) | |
| Reata Pharmaceuticals Inc ... | William D. McClellan | Director | Grant, award, or other acquisition of securities at price $ 93.61 per share. | 07 Jun 2023 | 1,682 | 6,017 (0%) | 0% | 93.6 | 157,452 | Class A common stock |
| Reata Pharmaceuticals Inc ... | William D. McClellan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2023 | 135 | 135 | - | - | Stock Option (right-to-buy) | |
| Reata Pharmaceuticals Inc ... | William D. McClellan | Director | Grant, award, or other acquisition of securities at price $ 93.61 per share. | 07 Jun 2023 | 106 | 4,335 (0%) | 0% | 93.6 | 9,923 | Class A common stock |
| Reata Pharmaceuticals Inc ... | William D. McClellan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2022 | 5,620 | 5,620 | - | - | Stock Option (right-to-buy) | |
| Reata Pharmaceuticals Inc ... | William D. McClellan | Director | Grant, award, or other acquisition of securities at price $ 34.76 per share. | 08 Jun 2022 | 3,883 | 4,229 (0%) | 0% | 34.8 | 134,973 | Class A common stock |
| Reata Pharmaceuticals Inc ... | William D. McClellan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2022 | 416 | 416 | - | - | Stock Option (right-to-buy) | |
| Reata Pharmaceuticals Inc ... | William D. McClellan | Director | Grant, award, or other acquisition of securities at price $ 34.76 per share. | 08 Jun 2022 | 287 | 346 (0%) | 0% | 34.8 | 9,976 | Class A common stock |
| Reata Pharmaceuticals Inc ... | William D. McClellan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2022 | 99 | 99 | - | - | Stock Option (right to buy) | |
| Reata Pharmaceuticals Inc ... | William D. McClellan | Director | Grant, award, or other acquisition of securities at price $ 27.32 per share. | 03 Jan 2022 | 59 | 59 (0%) | 0% | 27.3 | 1,612 | Class A common stock |
| Reata Pharmaceuticals Inc ... | William D. McClellan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2021 | 5,000 | 5,000 | - | - | Stock Option (right to buy) | |
| Reata Pharmaceuticals Inc ... | William D. McClellan | Director | 12 Nov 2020 | 4,000 | 4,000 (0%) | 0% | - | Class A common stock | ||
| Reata Pharmaceuticals Inc ... | William D. McClellan | Director | 12 Nov 2020 | 4,000 | 0 | - | - | Class B common stock | ||
| Reata Pharmaceuticals Inc ... | William D. McClellan | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Nov 2020 | 4,000 | 4,000 | - | - | Class B common stock | |
| Reata Pharmaceuticals Inc ... | William D. McClellan | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Nov 2020 | 4,000 | 2,000 | - | - | Stock Option (right to buy) | |
| Reata Pharmaceuticals Inc ... | William D. McClellan | Director | Sale of securities on an exchange or to another person at price $ 172.44 per share. | 12 Nov 2020 | 2,542 | 1,458 (0%) | 0% | 172.4 | 438,338 | Class A common stock |
| Reata Pharmaceuticals Inc ... | William D. McClellan | Director | Sale of securities on an exchange or to another person at price $ 173.21 per share. | 12 Nov 2020 | 970 | 488 (0%) | 0% | 173.2 | 168,018 | Class A common stock |
| Reata Pharmaceuticals Inc ... | William D. McClellan | Director | Sale of securities on an exchange or to another person at price $ 174.82 per share. | 12 Nov 2020 | 488 | 0 (0%) | 0% | 174.8 | 85,312 | Class A common stock |
| Reata Pharmaceuticals Inc ... | William D. McClellan | Director | 09 Nov 2020 | 4,000 | 0 | - | - | Class B common stock | ||
| Reata Pharmaceuticals Inc ... | William D. McClellan | Director | Sale of securities on an exchange or to another person at price $ 150.01 per share. | 09 Nov 2020 | 4,000 | 0 (0%) | 0% | 150.0 | 600,040 | Class A common stock |
| Reata Pharmaceuticals Inc ... | William D. McClellan | Director | 09 Nov 2020 | 4,000 | 4,000 (0%) | 0% | - | Class A common stock | ||
| Reata Pharmaceuticals Inc ... | William D. McClellan | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Nov 2020 | 2,500 | 4,000 | - | - | Class B common stock | |
| Reata Pharmaceuticals Inc ... | William D. McClellan | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Nov 2020 | 2,500 | 9,500 | - | - | Stock Option (right to buy) | |
| Reata Pharmaceuticals Inc ... | William D. McClellan | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Nov 2020 | 1,500 | 1,500 | - | - | Class B common stock | |
| Reata Pharmaceuticals Inc ... | William D. McClellan | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Nov 2020 | 1,500 | 0 | - | - | Stock Option (right to buy) |